BMY

Bristol-Myers Squibb Company (BMY) | Rumor.io

Bristol-Myers Squibb

BMY

Attention (50-day avg)0.01%

Attention rank (50-day avg)#633

Bullish sentiment (50-day avg)80%

Price to earnings ratio14

Market capitalization130.5B

Earnings per share4.54

Dividend yield (TTM)3.94%

Revenue (annual)48.2B

Net income (annual)7.1B

Social

What share of all stock conversation is about BMY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0% +0	0% -0.01	0.03% +0.01

Sep 29

Bristol-Myers Squibb's ($BMY) Phase 3 trial for admilparant has shown a potential liver safety issue.
Onureg, a treatment for AML, has shown extended Overall Survival (OS) in the QUAZAR trial, with a median OS of 67.6 months in CR1 and 35.5 months in patients 60 years and older.
Analysts are expecting a potential bottom for $BMY, with recent selling activity across multiple timeframes.

Generated by AI

Sentiment

Of the messages about BMY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	40% new	62.3% -37.7	82.18% +33.3	97.63% +16.79
Bearish	60% -40	37.7% new	17.82% -33.3	2.37% -16.79

Bullish· Aug 3

Bristol-Myers Squibb Company's pipeline rebuild and cost discipline are attracting investor attention, moving beyond concerns about patent cliffs.
Citigroup has raised its target price for BMY to $70 from $66, indicating a bullish outlook.
A potential merger between BMY and AstraZeneca could create one of the world's largest drugmakers, worth nearly $400 billion, according to reports.

Bearish· Dec 16

$BMY has dropped out of the portfolio after a 3-4 week run, with the author expecting a temporary setback before the upside is denied again.
$BMY is on its way down, with the author citing a horrible market as a contributing factor.
$BMY's monthly candle chart suggests the company is on its way down, with the author implying a negative trend.

Generated by AI

Topics

Of the messages about BMY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	57.14%	67.69%	68.12%	1.86%
Technical Analysis	34.29%	27.69%	11.43%	0.5%
Macro	0%	0%	7.97%	48.66%
Analysts	2.86%	1.54%	8.42%	48.7%
Earnings	0%	0%	0%	0.23%
Controversies	5.71%	3.08%	4.06%	0.05%

Earnings· Jul 30

Bristol-Myers Squibb ($BMY) raised its full-year guidance after beating Q2 expectations, with revenue increasing 6% to $12.97B and GAAP EPS more than doubling to $1.62.
The company raised its 2026 revenue guidance to a range of $49.0B to $50.0B, and increased its non-GAAP EPS range to $6.75 to $7.00.
Bristol-Myers Squibb's Q2 results were driven by strong performance in its Growth Portfolio, with Opdivo revenue increasing 15% to $2.485B, and a decline in its Legacy Portfolio.

Analysts· Dec 15

Bank of America upgraded Bristol-Myers Squibb to Buy from Neutral, citing a strong R&D pipeline and multiple upcoming catalysts through 2026.
The analysts raised the price target to $61 from $52, and view the stock's weakness as a buying opportunity due to the company's promising pipeline.
The upgrade and price target increase were driven by the company's strong research and development pipeline, which is expected to drive growth and earnings in the coming years.

Announcements· Aug 5

AstraZeneca and Bristol-Myers Squibb have no discussions about a potential deal, according to a senior source.
The companies have denied merger talks, with Reuters reporting that there was "never was a deal to be done."
The potential deal, which could have been worth over $400 billion, has been shut down, with sources confirming zero talks between the two pharmaceutical companies.

Controversies· Aug 2

Bristol-Myers Squibb (BMY) executive made $300,000 on insider trades on Amylin, Zymogenetics, Pharmasset, according to the SEC.
FBI agents arrested a Bristol-Myers Squibb executive on charges of insider trading, causing the stock to fall 7%.
Bristol-Myers Squibb suspended a mid-stage trial on its hepatitis C drug due to a "serious safety issue".

Technical Analysis· Dec 5

$BMY broke above its 50-day moving average, raising the possibility of a run to $70 or more, but a negative headline could send it back down.
$BMY has formed higher lows near $70, with a potential breakout above $73 pushing the stock toward $77, and RSI trends higher with volume confirming accumulation.
$BMY is stabilizing near $48.70 after a pullback, with a move above $49.20 potentially lifting the stock toward $50, and RSI is rising from oversold territory, signaling accumulation.

Generated by AI

Community

Of the messages about BMY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	37.5%	70.99%	78.97%	13.58%
Newcomers	62.5%	29.01%	21.03%	86.42%

Regulars· Sep 16

The SCOUT-HCM trial met its primary endpoint in symptomatic oHCM patients ages 12–18, showing safety similar to adults with no patient falling below 50% LVEF.
The stock is correcting near the previous resistance zone of $62.34 to $62.89, which might turn into support, with RSI also close to support.
The adolescent label and monitoring for the drug CAMZYOS are being closely watched after the trial's results.

Newcomers· Aug 5

Newcomers are discussing the potential deal between AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY), with some users expressing skepticism over the reported $400B+ deal value.
The denial of merger talks between $AZN and $BMY has caused a 6% spike in $AZN's stock price, indicating a significant impact on the market.
The rumor mill surrounding the potential deal has been put to rest by Reuters, which reported that there are no merger talks between the two companies.

Generated by AI

News

How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors

11h agoYahoo Finance

Potential liver safety issue seen in phase 3 trial for Bristol's admilparant

Phase 3 EU trial protocols flag potential liver safety risks for Bristol Myers Squibb’s admilparant in pulmonary fibrosis—see what it means for BMY.

15h agoSeeking Alpha

Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial

Bristol-Myers Squibb (NYSE:BMY) reported pivotal Phase 3 EXCALIBER-RRMM data for ZENBEXUS in relapsed or refractory multiple myeloma. The Phase 3 trial showed a clinically meaningful advantage in MRD-negative complete response rates versus standard therapy. The first full readout of EXCALIBER-RRMM highlights potential clinical and commercial relevance for ZENBEXUS in a crowded myeloma treatment field. The MRD-negative complete response results from EXCALIBER-RRMM are important, but investors...

17h agofinance.yahoo.com

Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers

1d agoYahoo Finance

3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.

1d agoYahoo Finance

Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook?

On September 25, Bristol-Myers Squibb Company (NYSE:BMY) announced milestone results from its Phase 3 EXCALIBER-RRMM trial evaluating Zenbexus in combination with daratumumab and dexamethasone (ZDd) for relapsed or refractory multiple myeloma. At a median follow-up of 15.7 months across 420 patients, ZDd demonstrated a statistically significant improvement in minimal residual disease (MRD)-negative complete response rates […]

1d agoYahoo Finance

Also Discussed

Investors talking about BMY also mention

#	Name	Attention
1	Merck & Co., Inc.MRK	0.01%-0.06
2	Novartis AG Sponsored ADRNVS	0%-0.01
3	Amgen Inc.AMGN	0.01%+0
4	GSK plc ADRGSK	0%0
5	AbbVie Inc.ABBV	0.03%-0.03
6	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
7	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
8	BioMarin Pharmaceutical IncBMRN	0%+0
9	Pfizer Inc.PFE	0.04%-0.01
10	Gilead Sciences, Inc.GILD	0%-0.04

Bristol-Myers Squibb Company

Healthcare
Drug Manufacturers - General

Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.

Website

Location

Route 206 & Province Line Road

Princeton, NJ, 08543

United States

Social

What share of all stock conversation is about BMY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0% +0	0% -0.01	0.03% +0.01

Sep 29

Bristol-Myers Squibb's ($BMY) Phase 3 trial for admilparant has shown a potential liver safety issue.
Onureg, a treatment for AML, has shown extended Overall Survival (OS) in the QUAZAR trial, with a median OS of 67.6 months in CR1 and 35.5 months in patients 60 years and older.
Analysts are expecting a potential bottom for $BMY, with recent selling activity across multiple timeframes.

Generated by AI

Sentiment

Of the messages about BMY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	40% new	62.3% -37.7	82.18% +33.3	97.63% +16.79
Bearish	60% -40	37.7% new	17.82% -33.3	2.37% -16.79

Bullish· Aug 3

Bristol-Myers Squibb Company's pipeline rebuild and cost discipline are attracting investor attention, moving beyond concerns about patent cliffs.
Citigroup has raised its target price for BMY to $70 from $66, indicating a bullish outlook.
A potential merger between BMY and AstraZeneca could create one of the world's largest drugmakers, worth nearly $400 billion, according to reports.

Bearish· Dec 16

$BMY has dropped out of the portfolio after a 3-4 week run, with the author expecting a temporary setback before the upside is denied again.
$BMY is on its way down, with the author citing a horrible market as a contributing factor.
$BMY's monthly candle chart suggests the company is on its way down, with the author implying a negative trend.

Generated by AI

Topics

Of the messages about BMY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	57.14%	67.69%	68.12%	1.86%
Technical Analysis	34.29%	27.69%	11.43%	0.5%
Macro	0%	0%	7.97%	48.66%
Analysts	2.86%	1.54%	8.42%	48.7%
Earnings	0%	0%	0%	0.23%
Controversies	5.71%	3.08%	4.06%	0.05%

Earnings· Jul 30

Bristol-Myers Squibb ($BMY) raised its full-year guidance after beating Q2 expectations, with revenue increasing 6% to $12.97B and GAAP EPS more than doubling to $1.62.
The company raised its 2026 revenue guidance to a range of $49.0B to $50.0B, and increased its non-GAAP EPS range to $6.75 to $7.00.
Bristol-Myers Squibb's Q2 results were driven by strong performance in its Growth Portfolio, with Opdivo revenue increasing 15% to $2.485B, and a decline in its Legacy Portfolio.

Analysts· Dec 15

Bank of America upgraded Bristol-Myers Squibb to Buy from Neutral, citing a strong R&D pipeline and multiple upcoming catalysts through 2026.
The analysts raised the price target to $61 from $52, and view the stock's weakness as a buying opportunity due to the company's promising pipeline.
The upgrade and price target increase were driven by the company's strong research and development pipeline, which is expected to drive growth and earnings in the coming years.

Announcements· Aug 5

AstraZeneca and Bristol-Myers Squibb have no discussions about a potential deal, according to a senior source.
The companies have denied merger talks, with Reuters reporting that there was "never was a deal to be done."
The potential deal, which could have been worth over $400 billion, has been shut down, with sources confirming zero talks between the two pharmaceutical companies.

Controversies· Aug 2

Bristol-Myers Squibb (BMY) executive made $300,000 on insider trades on Amylin, Zymogenetics, Pharmasset, according to the SEC.
FBI agents arrested a Bristol-Myers Squibb executive on charges of insider trading, causing the stock to fall 7%.
Bristol-Myers Squibb suspended a mid-stage trial on its hepatitis C drug due to a "serious safety issue".

Technical Analysis· Dec 5

$BMY broke above its 50-day moving average, raising the possibility of a run to $70 or more, but a negative headline could send it back down.
$BMY has formed higher lows near $70, with a potential breakout above $73 pushing the stock toward $77, and RSI trends higher with volume confirming accumulation.
$BMY is stabilizing near $48.70 after a pullback, with a move above $49.20 potentially lifting the stock toward $50, and RSI is rising from oversold territory, signaling accumulation.

Generated by AI

Community

Of the messages about BMY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	37.5%	70.99%	78.97%	13.58%
Newcomers	62.5%	29.01%	21.03%	86.42%

Regulars· Sep 16

The SCOUT-HCM trial met its primary endpoint in symptomatic oHCM patients ages 12–18, showing safety similar to adults with no patient falling below 50% LVEF.
The stock is correcting near the previous resistance zone of $62.34 to $62.89, which might turn into support, with RSI also close to support.
The adolescent label and monitoring for the drug CAMZYOS are being closely watched after the trial's results.

Newcomers· Aug 5

Newcomers are discussing the potential deal between AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY), with some users expressing skepticism over the reported $400B+ deal value.
The denial of merger talks between $AZN and $BMY has caused a 6% spike in $AZN's stock price, indicating a significant impact on the market.
The rumor mill surrounding the potential deal has been put to rest by Reuters, which reported that there are no merger talks between the two companies.

Generated by AI

Bristol-Myers Squibb

Social

Sep 29

Bullish· Aug 3

Bearish· Dec 16

Earnings· Jul 30

Analysts· Dec 15

Announcements· Aug 5

Controversies· Aug 2

Technical Analysis· Dec 5

Regulars· Sep 16

Newcomers· Aug 5

How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors

Potential liver safety issue seen in phase 3 trial for Bristol's admilparant

Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial

Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers

3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation

Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook?

Also Discussed

Bristol-Myers Squibb Company

Company Information

Location

How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors

Potential liver safety issue seen in phase 3 trial for Bristol's admilparant

Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial

Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers

3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation

Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook?

Also Discussed

Social

Sep 29

Bullish· Aug 3

Bearish· Dec 16

Earnings· Jul 30

Analysts· Dec 15

Announcements· Aug 5

Controversies· Aug 2

Technical Analysis· Dec 5

Regulars· Sep 16

Newcomers· Aug 5